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Increased responsivenessof vascular cells tothe growth factorIGF-Ihas been implicated incomplications associated withdiabetes.
Here we describe the development of an assay and screening of a library of compounds for their ability to accelerate cleavage
of the transmembrane protein integrin-associated protein (IAP) thereby disrupting the association between IAP and SHPS-1
which we have shown as critical for the enhanced response of vascular cells to IGF-I. The cell-based ELISA utilizes an antibody
that speciﬁcally detects cleaved, but not intact, IAP. Of the 1040 compounds tested, 14 were considered active by virtue of their
ability to stimulate an increase in antibody-binding indicative of IAP cleavage. In experiments with smooth muscle and retinal
endothelial cell cultures in hyperglycemic conditions, each active compound was shown to accelerate the cleavage of IAP, and
this was associated with a decrease in IAP association with SHPS-1 as determined by coimmunoprecipitation of the proteins
from cell lysates. As a consequence of the acceleration in IAP cleavage, the compounds were shown to inhibit IGF-I-stimulated
phosphorylation of key signaling molecules including Shc and ERK1/2, and this in turn was associated with a decrease in IGF-
I-stimulated cell proliferation. Identiﬁcation of these compounds that utilize this mechanism has the potential to yield novel
therapeutic approaches for the prevention and treatment of vascular complications associated with diabetes.
Copyright © 2009 Laura A. Maile et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Increased cellular responsiveness to insulin-like growth
factor-I (IGF-I) has been implicated in several complications
associated with diabetes including vascular complications
such as atherosclerosis [1–3] and diabetic retinopathy [4–
6] as well as other complications such as neuropathy [7–
16]. Directly targeting IGF-I or its receptor; however, is likely
to be associated with unwanted side eﬀects. Our long-term
goalistodeveloptherapeuticstrategiesthatcouldspeciﬁcally
antagonizetheeﬀectsofIGF-Iassociatedwithhyperglycemia
yet preserve IGF-I’s beneﬁcial eﬀects.
People with both type 1 and type 2 diabetes develop
atherosclerosis at a signiﬁcantly accelerated rate compared
to non diabetics [17–19]. Recent studies have suggested that
hyperglycemia plays a signiﬁcant role in the acceleration of
lesion initiation and progression in patients with both type 1
a n dt y p e2d i a b e t e s[ 20–22]. Proliferative diabetic retinopa-
thy (PDR) is characterized by the growth of unwanted
blood vessels and intravitreous neovascularization (IVNV)
[23]. Formation of these new blood vessels requires retinal
endothelial cell (REC) proliferation and migration [24].
Hyperglycemia appears to contribute directly to both SMC
proliferation and migration associated with atherosclerosis
[25].and the neovascularization associated with PDR [21].
Insulin-like growth factor-I (IGF-I) stimulates SMC migra-
tion and proliferation and has therefore been implicated in
the lesion progression [1–3]. Similarly various studies have
implicated IGF-I as a contributor to the retinal neovascu-
larization associated with PDR [4–6]. Both REC and SMC
growninhighglucosearemoreresponsivetothestimulatory
eﬀects of IGF-I compared to cells grown in normal glucose
[26].
Activation of the intrinsic kinase activity of the IGF-
I receptor (IGF-IR) is required to trigger downstream
signaling events that lead to cellular proliferation. There is
no diﬀerence in abundance or extent of IGF-IR activation
between SMC grown in normal or high glucose; therefore,2 Experimental Diabetes Research
this does not account for the diﬀerence in response to IGF-
I[ 26]. The proliferative response of both REC and SMC to
IGF-I in hyperglycemia is dependent upon the interaction
between the extracellular domains of two transmembrane
proteins, integrin-associated protein (IAP) and SHP sub-
strate 1 (SHPS-1) [27]. When IAP is bound to SHPS-1,
tyrosine residues within the cytoplasmic domain of SHPS-
1 are phosphorylated in response to activation of the IGF-IR
[27]. Phosphorylation of these tyrosine residues is required
for the recruitment of signaling molecules to SHPS-1 and
their recruitment is required to elicit an increase in SMC
proliferation in response to IGF-I [28, 29]. Our studies
have shown that when REC and SMC are grown in 5mM
glucose conditions the extracellular domain of IAP is cleaved
and the residual IAP fragment that remains cell-surface
associated cannot bind SHPS-1 [30, 31]. When vascular
c e l l sa r eg r o w ni nh i g hg l u c o s e( e . g . ,>12mM), IAP is
protected from cleavage and there is a signiﬁcant increase in
its interaction with SHPS-1. This in turn is associated with
increased SHPS-1 phosphorylation, enhanced activation of
downstream signaling events and increased cell proliferation
in response to IGF-I [31, 32]. These observations led us to
hypothesize that stimulation of IAP cleavage in the presence
of hyperglycemia could be a novel strategy for the inhibition
of IGF-I-stimulated REC and SMC proliferation.
The Juvenile Diabetes Research Foundation (JDRF) in
conjunction with National Institutes of Health-National
Institutes of Diabetes and Digestive Kidney Disease
(NIDDK) funded a program to screen a panel of 1040
selected compounds for the prevention of cellular dysfunc-
tion in various cell types that are relevant to diabetic com-
plications (a document containing a summary of the various
assays that were developed and the outcomes is available
online (http://www.t1diabetes.nih.gov/Investigator/Drug-
ScreeningSummary-Final.doc)). In response to this program
we designed, implemented and validated a cell-based
ELISA that measured the ability of each compound to
accelerate IAP cleavage in SMC grown in high glucose. In
this study we describe the initial testing of the compounds
leading to the identiﬁcation of 14 compounds that were
analyzedfortheirabilitytoinhibitIGF-Isignalinginvascular
cells.
2.MaterialsandMethods
2.1.Materials. Human,endotoxin-free,IGF-Iwasagiftfrom
Genentech (South San Francisco, CA). Polyvinyl diﬂuoride
membrane (Immobilon P) was purchased from Millipore
Corporation (Billerica, MA). Cl-Xposure autoradiographic
ﬁlm was obtained from Pierce (Rockford, IL). Fetal Bovine
Serum, Dulbecco’s modiﬁed medium, penicillin and strep-
tomycin were purchased from Life Technologies, (Grand
Island, NY). The monoclonal antiphosphotyrosine antibody
(PY99) was purchased from Santa Cruz (Santa Cruz, CA).
The anti-Shc and phospho/total ERK1/2 antibodies were
purchased from BD Transduction Laboratories (Lexington,
KY). The anti-SHPS-1 antibody was purchased from Upstate
Cell Signaling Solutions (Charlottesville, VA). All other
reagents were purchased from Sigma Chemical Company (St
Louis, MO) unless stated.
2.2. Anti-IAP Antibodies. The anti-IAP monoclonal anti-
body, B6H12, was puriﬁed from a speciﬁc cell line derived
from a B-cell hybridoma as we have described previously
[33]. The anti-IAP antibodies were generated by conjugat-
ing a peptide to keyhole limpet hemagglutinin and used
for immunization as we have described previously [34].
Antibody R569 was generated using a peptide homologous
to amino acids 41–61 of the extracellular domain of IAP
(KGRDIYTFDGALNKSTVPTC) [31]; R593 was generated
using a peptide homologous to amino acids 74–96 of the
extracellulardomainandR250wasgeneratedusingapeptide
homologous to amino acids 279–292 [31]. Serum from a
nonimmunized rabbit was used as control antiserum.
2.3. Porcine SMC. SMC were isolated from porcine aortic
explants by a modiﬁcation of the protocol by Ross [35]
as we have described previously [26]. Following isolation
SMCweremaintainedineitherhighglucosegrowthmedium
(HG-GM) (DMEM containing 4500g/L (25mM) glucose)
or normal glucose (NG-GM) (DMEM containing 900g/L of
glucose (5mM)) plus 10% fetal bovine serum (FBS), peni-
cillin (1000U/mL), streptomycin (160μg/mL) and 0.5mM
sodium pyruvate. SMC were fed every 3 days with either
HG- or NG-GM and were passed every 7 days in the
appropriate medium. All experiments were performed on
SMC between passage number 4 and 10. We have previously
determined that SMC cultured under these two diﬀerent
conditions do not diﬀer signiﬁcantly in their diﬀerentiation
status[26].Tocontrolfordiﬀerencesinosmolarity,mannitol
(19.5mM) was added to the NG-serum-free medium [26].
We have determined previously that the presence or absence
of mannitol does not inﬂuence the responses of SMC grown
in NG [26].
2.4. Retinal Endothelial Cells. Primary bovine RECs were
obtainedfromVECTechnologiesInc(Rensselaer,NY).Stock
culturesofRECsweregrowninadeﬁnedECgrowthmedium
(MCDB-131 complete) supplied by VEC Technologies Inc
which contains 5mM glucose. Stock cultures of RECs were
grown in 10cm dishes precoated with 50μg/mL ﬁbronectin
in PBS for 30 minutes at 37◦C. To examine the eﬀects of the
compounds in high glucose the medium was supplemented
to 25mM glucose as we have described previously [30].
2.5. Primary Screening of Compounds: Assay Design and
Validation. SMC were maintained in 10cm dishes in HG-
GM. For individual experiments SMC were plated in 96 well
plates (Falcon) in HG-GM at a density of 5000 cells per well.
SMCs were grown to conﬂuency over a period of 5 days with
no media change.
2.5.1.Antibodies. Positivecontrol:Themonoclonalantibody
B6H12 binds equally well to IAP in both normal and high
glucose, that is, it does not distinguish between intact or
cleaved IAP. Therefore the binding of this antibody was usedExperimental Diabetes Research 3
to control for total amount of IAP [31]. Negative Control:
Antibody R250 is a polyclonal antibody raised in rabbits
with a peptide homologous to amino acids 279 to 292 of
human IAP (VASDHKTIQPPRNN). This region of IAP is
the most C-terminal region of the cytoplasmic domain and
therefore served as a negative control since this region of
IAP is not surface exposed and can not bind to IAP when
cells are intact. Test Antibody: Antibody R593 is a polyclonal
antibody raised in rabbits against a peptide homologous to
amino acids 74 to 96 of the mature human IAP sequence
(KGDASLKMDKSDAVSHTGNYT). R593 binds to cleaved
IAP with a higher aﬃnity than to that of intact IAP due to
exposure of a neo-epitope following cleavage.
Characterization of the antibodies is shown in supple-
mentary Figure 1 in supplementary material available online
at doi:10.1155/2009/267107.
2.5.2. Reagents. Serum-free medium (SFM) plus was pre-
pared by mixing DMEM (HG or NG) with 20mM HEPES,
0.2% BSA, and 0.02% Sodium Azide. This was prepared
immediately before use and kept on ice for the duration
of the assay. A diethanolamine (DEA) buﬀer stock solution
was prepared, stored at 4◦C, and protected from light. For
500mL of buﬀer, 4.8mL of 85% diethanolamine (Fisher Cat
no.D45)and0.25mLof1MMgCl2 weremixedwith995mL
of water. Immediately before use, the alkaline phosphatase
substrate solution was prepared by mixing 20mL of DEA
buﬀerwithonetabletofPara-nitrophenylphosphate(pNPP)
(Sigma Cat no. N2765).
2.5.3. Treating Cells with Test Compounds. Prior to initiating
the assays, treatments were prepared in SFM. For each assay
9 wells were incubated in NG-SFM alone and the remaining
wells were incubated with HG-SFM glucose plus or minus
test or control. The control compounds were (a) the heparin
binding domain of vitronectin and (b) the IAP binding
domain of thrombospondin. Both control compounds have
been shown to inhibit IAP cleavage (data not shown).
Cell monolayers were washed three times with serum free
medium (SFM) and then 100μL of SFM plus or minus the
treatments or controls was added. For each assay nine wells
were rinsed and then SFM containing 5mM glucose was
added.NineadditionalwellsreceivedHG-SFMaloneandthe
remaining wells received either test or control compounds
in HG-SFM. The 96 well plate was then placed in a 37◦C
incubator (5% CO2 and 80% humidity) for six hours. Each
compound was tested at three concentrations (2, 5 and
10μM).
2.5.4.IncubationwithPrimaryAntibodies. Aftersixhoursthe
plate was placed on ice. SFM was aspirated from each well
and the wells were rinsed three times with 100μLo fS F M
containing 0.2% bovine serum albumin, 20mM HEPES and
0.0% sodium azide (SFM plus). Following rinsing with SFM
plus the cell monolayer was incubated with the appropriate
primaryantibody preparedinSFMplus.Fortheninecontrol
wells(incubatedwitheitherhigh-ornormal-glucosemedia),
three wells were exposed to 100μL of B6H12 (at a dilution of
1 : 100), the negative control antibody R250 (at a dilution
of 1 : 100) or with the test antibody R593 (at a dilution of
1 : 100). The remaining wells were exposed to a 1 : 100
dilution of R593. The plates were then incubated overnight
at 4◦C with gentle rocking.
2.5.5. Incubation with Secondary Antibodies. Following the
overnight incubation the plates were placed on a tray of
ice and each is well aspirated. They were rinsed three
times with SFM plus prior to incubation with appropriate
secondary antibody. Wells that had been exposed to B6H12
were incubated with 100μL of a 1 : 500 dilution of a
goat antimouse alkaline phosphatase conjugated secondary
antibody and the wells incubated with the R593 or R250
polyclonal antibodies were incubated with 100μLo fa1:
500 dilution of the goat anti-Rabbit conjugated secondary
antibody. The incubation proceeded for one hour at room
temperature with gentle rocking.
2.5.6. Addition of Alkaline Phosphate Substrate and Color
Development. 5 minutes before the end of the one hour
incubation the alkaline phosphatase substrate developing
solution was prepared. After one hour the secondary anti-
body was removed and the wells were washed three times
with SFM plus. 50μL of the alkaline phosphatase developing
solution was then added to each well and the color was
allowed to develop being protected from light for 20 minutes
at room temperature. The yellow color of nitrophenol was
measured at 405nm giving an optical density (OD) reading
for each treatment.
2.5.7. Data Analysis. The OD reading determined after
antibody binding to SMC exposed to HG was subtracted
from the OD reading for antibody binding to SMC exposed
to NG. This value was referred to as ΔODmax.T h eO D
reading for antibody binding to SMC treated with HG was
then subtracted from the OD reading for each compound
(ΔODtest). A percent score for each compound was then
calculatedbythefollowingequation:ΔODtest/ΔODmax×100.
2.5.8. Criteria for Identiﬁcation of Positive Hit. Ac o m p o u n d
was considered active if, in the presence of the compound,
the increase in the amount of antibody (that speciﬁcally
recognizes cleaved IAP) bound to cells in HG was at least
75% of the value obtained when antibody binding was
quantiﬁed in NG. Therefore the percent score is a measure of
the ability of the compound (at 10μM) to increase antibody
binding. The compounds that achieved this result were then
tested over a range from 0.2μMt o1 0 μM (0.2, 0.5, 2,
5, 10μM). The concentration of compound in which the
increase in antibody binding to cells in high glucose was
50% of the diﬀerence between antibody binding to cells in
normal glucose as compared to high glucose was considered
the ED50.
2.6. Immunoblotting to Validate Primary Screening Results.
To conﬁrm that the compounds that increased antibody
binding in the ELISA could alter IAP cleavage, REC or4 Experimental Diabetes Research
SMC that had been maintained in HG-GM were exposed to
the compounds then lysates were prepared and analyzed by
immunoblottingusingeithertheanti-IAPantibodythatonly
recognizes intact IAP (R569) or the monoclonal antibody
B6H12 that recognizes both intact and the residual mem-
brane associated fragment of IAP ([31] and supplementary
Figure 1). REC and SMC were plated in 10cm dishes in
HG- or NG-GM and grown to conﬂuency for 7 days with
the medium being changed every 2-3 days. On day 7 the
growth medium was removed and the conﬂuent monolayers
were rinsed three times with SFM-HG or NG then incubated
overnight (16-17 hours). The compounds were then added
for 6 hours. Cells were lysed in a modiﬁed RIPA buﬀer.
Following centrifugation, equal amounts of cellular protein
(as determined using the BCA protein assay (Pierce) data
not shown) were mixed with nonreducing gel loading buﬀer,
heated to 70◦C for 10 minutes and separated by SDS-
PAGE (8%). Following SDS-PAGE, IAP was visualized by
immunoblotting as we have previously described [33].
2.7. Assays to Determine Whether Compounds That Accelerate
IAP Cleavage Inhibit IGF-I Signaling in High Glucose
2.7.1. Cell Proliferation. Cell proliferation assays were per-
formed as we have described previously [36]. SMCs were
plated at 2 × 104 cells per well in each well of a 24 well plate
in HG-SFM or NG-SFM plus 2% FBS. Cells were allowed
to attach overnight before the medium was replaced with
fresh SFM. 24 hours later the SFM was replaced with SFM
+ 0.2% platelet poor plasma (PPP) with or without the
additionofIGF-I(50ng/mL).Thecompoundswereaddedat
a concentration of 5μM immediately prior to the addition of
IGF-I.Cellnumberwasdeterminedfollowingtrypsinization,
trypan blue staining and counting [29].
2.7.2. Cell Lysis, Immunoprecipitation and Western Immunob-
lotting. R E Ca n dS M Cc u l t u r e sw e r ee x p o s e dt ot e s t
reagents as described above for the secondary screening
assay. Immunoprecipitation studies (using anti-SHPS-1 and
Shc antibodies) were performed as previously described
[33]. Following SDS-PAGE the proteins were visualized by
immunoblotting as we have previously described [33]. For
immunoblotting the antibodies (B6H12, R569, SHPS-1, p-
Tyr, Shc, pERK1/2) were used at concentrations between
1 : 500 and 1 : 1000.
2.8. Statistical Analysis. Chemiluminescent images obtained
were scanned using a DuoScan T1200 (AGFA Brussels,
Belgium) and band intensities of the scanned images were
analyzed using NIH Image, version 1.61. The Student’s t-test
was used to compare diﬀerences between treatments. The
results that are shown, expressed as the mean ± SEM, are
representative of at least three separate experiments.
3. Results
3.1. Primary Screening. The ELISA that measures the degree
of proteolytic cleavage of IAP in the presence and absence
of test compounds in SMC in 25mM glucose relies on
an antibody (R593) that recognizes a neo-epitope whose
aﬃnity for the antibody is increased following cleavage
(supplementary Figure 1). Of the 1040 compounds tested
14 were considered “positive hits” according to the criteria
described in Section 2. These are listed in Table 1. Further
analysis of these compounds allowed determination of the
ED50 and the eﬀective concentration range (Table 1).
3.2. Secondary Screening (SMC). In contrast to the primary
screening assay that utilized an antibody that speciﬁcally
detected IAP cleavage, the secondary screening assays used
one of two antibodies, R569, that binds to the cleaved
portion of IAP and thus does not recognize the residual
transmembrane fragment that remains following cleavage or
the anti-IAP monoclonal antibody, B6H12, which recognizes
both intact and the residual membrane fragment [31].
The results from these assays were determined by western
immunoblotting rather than ELISA. Treatment of SMC with
each of the 14 compounds resulted in signiﬁcant decrease in
the amount of intact IAP that could be detected (Figure 1(a)
shows an example of the results obtained using compounds
1–3 and the data are summarized for all 14 compounds in
Table 2).
3.3. Secondary Screening (REC). We then tested compounds
1 through 3 for their ability to accelerate IAP cleavage in
REC grown in high-glucose medium (Figure 1(b)). All 3
compounds signiﬁcantly decreased the amount of intact IAP
that could be detected compared with REC grown in high
glucose.
3.4. Eﬀect of “Positive Hit” Compounds on IAP Association
with SHPS-1. Our previous studies have shown that in
order for IGF-I to stimulate an increase in both REC and
SMC migration and proliferation a speciﬁc signaling com-
plex must be formed. Speciﬁcally, the two transmembrane
proteins, IAP and SHPS-1 must associate, via their extra-
cellular domains which permits SHPS-1 phosphorylation
in response to IGF-I [27]. Phosphorylation of SHPS-1 is
necessary for the formation of the SHP-2-Src-Shc complex
which leads to the subsequent phosphorylation of Shc and
activation of the MAP and PI-3 kinase signaling pathways
since both of which are required for IGF-I-stimulated
migration and proliferation [29]. When RECs or SMCs are
maintained in 5mM glucose SHPS-1 is not phosphorylated
therefore this complex does not form due to the cleavage of
IAP [30, 31]. Thus, to determine the eﬀectof the compounds
that accelerate IAP cleavage on IGF-I signaling we examined
formation of the IAP-SHPS-1 signaling complex.
Each compound signiﬁcantly reduced the association of
IAP with SHPS-1 (Figure 2(a) and Table 2). The signiﬁcance
of IAP-SHPS-1 disruption was assessed by measuring SHPS-
1 phosphorylation. In the presence of each compound the
ability of IGF-I to stimulate SHPS-1 phosphorylation was
signiﬁcantly impaired (Figure 2(b) and Table 2).
The disruption in IAP-SHPS-1 association and inhi-
bition of SHPS-1 phosphorylation would be predictedExperimental Diabetes Research 5
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Figure 1: Acceleration of IAP cleavage by positive hit compounds (a) and (b). SMCs were grown to conﬂuency in DMEM containing 25mM
glucose and then incubated overnight in SFM. They were then incubated in HG-SFM alone or HG-SFM containing the test compounds (2, 5
or 10μM) for 6 hours. Following lysis and separation by SDS-PAGE the amount of intact IAP was detected by western immunoblotting with
theanti-IAPmonoclonalantibody,B6H12whichrecognizesintactandresidualmembraneassociatedIAPfragmentortheanti-IAPantibody
R569 which speciﬁcally recognizes intact IAP. To control for diﬀerences in protein equal amounts of lysate were also immunoblotted with
the anti-SHPS-1 antibody. (c) REC were maintained in medium containing 25mM glucose prior to incubation overnight in SFM. The test
compounds were added at a concentration of 5μMf o r6h o u r s .I A Pw a sv i s u a l i z e da sd e s c r i b e da b o v e .
Table 1: Ranking of compounds that accelerate IAP cleavage.
Number Compound ED50 (μM) Active range (μM)
Mean % increase
in R593 binding
(5μM)
1 l-leucyl alanine 0.5 0.2–10 96 ±0.8
2 n-formyl methionyl leucyl phenylalanine 0.75 0.2–10 100 ±5
3 Mephentermine sulfate 1 0.2–10 90 ±5
4 Lysyl tyrosyl lysine acetate 2 0.2–10 75 ±20
5 Dopamine hydrochloride 2 1–10 84 ±8
6 N formyl methionyl phenylalanine 2 1–10 75 ±5
7 Dyclonine hydrochloride 2.5 1–10 92 ±8
8 Amoxicillin 3 1–10 85 ±2
9 Hydralazine hydrochloride 3 1–10 76 ±7.5
10 Cephaloride 4 2–10 65 ±5
11 Dinitolmide 5 2–10 35 ±12
12 Acetyl cysteine 6 2–10 30 ±5
13 Pyridostigmine bromide 6.5 1–10 30 ±1
14 Chloropromazine 7 2–10 25 ±2
to inhibit downstream signaling. Each compound signiﬁ-
cantly inhibited IGF-I stimulation of Shc phosphorylation
(Figure 3(a) and Table 2) and Shc recruitment to SHPS-
1( Figure 3(b) and Table 2) .O u rp r e v i o u ss t u d i e sh a v e
shown that the phosphorylation of Shc is required for
activation of downstream signaling pathways including the
MAPK pathway. Consistent with the signiﬁcant decrease
in Shc phosphorylation, activation of MAPK, as shown
by analysis of the phosphorylated forms of ERK1/2 in
response to IGF-I, was also signiﬁcantly impaired in the
presence of each of the 14 compounds (Figure 3(c) and
Table 2).
In 25mM glucose these changes led to enhanced SMC
proliferation in response to IGF-I. When SMCs were main-
tained in 25mM glucose IGF-I-stimulated a signiﬁcant, 3
fold increase in SMC proliferation. In contrast, the addition
of each compound resulted in at least a 2 fold decrease in
IGF-I-stimulated proliferation (Figure 4 and Table 2).
4. Discussion
Atherosclerosis represents the leading cause of death in both
type 1 and type 2 diabetes [37–39]. Intensive multifactorial
treatment of hyperglycemia, dyslipidemia and hypertension6 Experimental Diabetes Research
Table 2: Eﬀect of compounds on IAP cleavage, IAP-SHPS-1 association and IGF-I-stimulated signaling events.
Compound
number
Decrease in
R569 binding∗
IAP-SHPS-1
association∗∗
SHPS-1
phosphor∗∗
SHPS-1-Shc
association∗∗ Shc phosphor∗∗ ERK
Phosphor∗∗
19 7 ± 28 0 ± 5 87.5 ± 12 96.5 ± 3 76 ± 8 93 ± 5
29 1 ± 1.5 97 ± 29 3 ± 7 95.5 ± 4 77 ± 13 84 ± 14
38 5 ± 3 100 ± 09 9 ± 18 9 ± 0.5 81 ± 10 84 ± 9
46 3 ± 18 58 ± 15 94 ± 58 5 ± 5 65 ± 10 79 ± 13
58 0 ± 65 2 ± 17 7 ± 14 90 ± 2 83 ± 4 70 ± 13
67 8 ± 65 5 ± 10 90 ± 59 3 ± 1.5 85 ± 7 65 ± 15
78 3 ± 39 2 ± 17 6 ± 14 94 ± 3 80 ± 20 85 ± 12
87 8 ± 15 5 ± 57 6 ± 78 4 ± 7 66 ± 16 92 ± 1
97 0 ± 82 1 ± 25 0 ± 28 84 ± 6 90 ± 5 73 ± 12
10 78 ± 2.5 90 ± 88 5 ± 88 6 ± 5 57 ± 7 82 ± 8
11 50 ± 56 0 ± 12 90 ± 47 5 ± 10 65 ± 15 90 ± 4
12 78 ± 4.5 55 ± 58 9 ± 11 78 ± 2 78 ± 2 99 ± 1
13 45 ± 59 7 ± 19 0 ± 10 84 ± 3 73 ± 4 89 ± 4
14 72 ± 46 6 ± 74 7 ± 56 7 ± 2.5 77 ± 3 92 ± 1
∗% Decrease in R569 antibody binding compared with SMC maintained in 25mM glucose.
∗∗% Decrease in association, phosphorylation or recruitment in response to IGF-I compared with SMC maintained in 25mM glucose.
Results shown are mean ± sem N = 3.
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IB: SHPS-1
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12 3
IGF-I (mins)
Compound (5μm)
(b)
Figure 2: Acceleration of IAP cleavage inhibits IAP-SHPS-1 association and SHPS-1 phosphorylation. SMCs were grown to conﬂuency in
DMEM containing 25mM glucose and then incubated overnight in SFM. They were then incubated in HG-SFM or HG-SFM containing the
test compounds (mM) for 6 hours. Where indicated the cultures were treated with IGF-I (100ng/mL) for 5 minutes prior to lysis. Cell lysates
were then immunoprecipitated and proteins visualized by western immunoblotting. To control for diﬀerences in total protein samples were
also immunoblotted with an anti-SHPS-1 antibody. (a) IAP association with SHPS-1 was determined following immunoprecipitation (IP)
with an anti-SHPS-1 antibody and immunoblotting (IB) with the anti-IAP monoclonal antibody, B6H12. (b) SHPS-1 phosphorylation in
response to IGF-I was determined by IP with an anti-SHPS-1 antibody and IB with an antiphosphotyrosine antibody (p-Tyr). To control for
diﬀerences in total protein samples were also immunoblotted with an anti-SHPS-1 antibody.
can signiﬁcantly reduce the incidence of cardiovascular
disease but only a small percentage of patients is able to
manage all these factors to achieve suﬃcient control to lower
their risk [40]. Thus there is a need for a systemic therapy
that inhibits the progression of the disease in these patients.
Proliferative retinopathy is one of the most severe and
prevalent complications of diabetes. 34 years after disease
onset patients who were diagnosed prior to age 30 have a
prevalence of 70%. Even with improved glycemic control the
probability of developing diabetic retinopathy after having
had type 1diabetes for 30 years is greater than 60%. Because
of this high prevalence diabetic retinopathy remains the
secondleadingcauseofblindnessinindividualsover60years
ofage.Aspatientswithtype1diabetescontinuetolivelonger
the prevalence of loss of vision due to diabetic retinopathy is
likely to increase. Therefore there will continue to be a needExperimental Diabetes Research 7
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Figure 3: Acceleration of IAP cleavage inhibits signaling in response to IGF-I. SMCs were grown to conﬂuency in DMEM containing 25mM
glucose and then incubated overnight in HG-SFM. SMC were then incubated in HG-SFM, NG-SFM (5mM) or HG-SFM containing the
test compounds (μM) for 6 hours. Where indicated the cultures were treated with IGF-I (100ng/mL) for 5 minutes prior to lysis. Cell lysates
were then used for immunoprecipitation and proteins visualized by western immunoblotting. (a) Shc phosphorylation in response to IGF-I
was determined by IP with an anti-Shc antibody and IB with an antiphosphotyrosine antibody (p-Tyr). (b) Shc association with SHPS-1 was
determined following immunoprecipitation (IP) with an anti-SHPS-1 antibody and immunoblotting (IB) with an anti-Shc antibody. (c)
MAPK activation was assessed by immunoblotting lysates directly with an antibody that speciﬁcally recognizes the phosphorylated forms of
ERK1/2 (pERK). (d) To control for loading samples were immunoblotted with an anti-ERK antibody.
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Figure 4: Inhibition of IGF-I-stimulated SMC proliferation.2× 104
cells were plated in each well of a 24 well plate prior to exposure to
IGF-I(50ng/mL),andthetestcompounds(allpreparedinDMEM-
H+0.2%plateletpoorplasma).48hoursaftertheadditionofIGF-I
(50ng/mL)cellnumberwasdeterminedbytrypanbluestainingand
counting. ∗P<. 05 when cell in response to IGF-I is compared with
the number of cells in DMEM-H alone.
in patients with type 1 diabetes for this type of therapeutic
approach. Treatment of this disorder has been through
either technical procedures such as photocoagulation [41]
and vitrectomy [42] or preventative measures such as
reduction in hyperglycemia [43] and blood pressure [44].
Three therapies have been introduced based on inhibiting
pathophysiologicchangesinbiochemicalsignalingpathways.
The most eﬀective is inhibition of vascular endothelial
growth factor (VEGF), a mitogen for retinal vein endothelial
cells[45]. When VEGF antibodies are directly injected into
eyes of human subjects they limit the proliferative phase
of the disease [46]. Similarly enhanced activation of the
protein kinase C beta pathway is present and an orally
active, PKC beta inhibitor reduces retinopathy progression
[47]. Treatments which lower serum IGF-I concentrations
have been tried but because of their relative ineﬀectiveness
in lowering serum IGF-I concentrations they had limited
eﬃcacy [48].
The focus of our studies has been to identify prevention
and treatment strategies for the vascular complications
that are associated with diabetes by identifying signaling
events that are speciﬁc for the hyperglycemic environment.
Identiﬁcation of such targets has the potential for the
development of therapies that will prevent the disease asso-
ciated events without disrupting the normal function of the
cells.
Increased activity of IGF-I has been implicated in both
atherosclerosis and diabetic retinopathy. Since our previous
studies have shown that both REC and SMC grown in high
glucose are more responsive than those grown in normal
glucose [26] and that the diﬀerence in responsiveness is
due to regulation of IAP cleavage [30, 31] we hypothesized
that acceleration of IAP cleavage was a potential strategy for
the inhibition of IGF-I-stimulated vascular cell proliferation
speciﬁcally in hyperglycemic conditions. In this study we
screened 1040 compounds for their ability to accelerate IAP
cleavage in a cell-based ELISA using an antibody speciﬁc for
the cleaved form of IAP. While the extent of IAP cleavage
stimulated by the addition of each compound varied, in each8 Experimental Diabetes Research
case the extent of IAP cleavage was suﬃcient to signiﬁcantly
disrupt IAP-SHPS-1 association. We have shown previously
that disrupting IAP-SHPS-1 association with the anti-IAP
antibody, B6H12, inhibits IGF-I-stimulated signaling [27].
The results show that each compound inhibited SHPS-
1 phosphorylation [27]. Additionally, the recruitment and
phosphorylation of Shc which is necessary for activation of
downstream signaling pathways [29]i nr e s p o n s et oI G F -
I was signiﬁcantly impaired in the presence of each of
the active compounds. Given the importance of IAP in
regulating the response of REC and SMC to IGF-I it is
reasonable to conclude that identiﬁcation of compounds
that can disrupt the hyperglycemia induced increase in
IAP-SHPS-1 association has the potential to inhibit IGF-I
signaling in vascular cells in vivo.
Ofthemostactivecompoundstheycouldbedividedinto
three groups. Both Pyridostigmine bromide and Cephalori-
dine are quarternary pyridinium compounds. The second
grouparealldipeptideanalogs(e.g.,n-formylmethionylleu-
cly phenylalanine). The third group are arylalkylamino com-
pounds including chloropromazine, dopamine, hydralazine
and mephenentermine. Studies will now be required to iden-
tify the molecular pathways stimulated by each compound
that mediate their eﬀects on IAP cleavage. In particular, it
will be of interest to determine whether there is convergence
between signaling pathways triggered by the diverse group of
compounds identiﬁed.
We have determined that the protease responsible for
the cleavage of IAP when SMCs are maintained in normal
glucose is MMP-2 [31]. Conversion of MMP-2 to the fully-
active form is a multistep process involving the formation
of a complex including the membrane-bound MT1-MMP
which binds to TIMP-2 which in turn binds to pro-MMP-
2. This complex then catalyzes the conversion of MMP-2 to
theintermediateandthenactiveformoftheenzyme[49–56].
Further studies will be required to determine whether these
compounds alter the amount of MMP-2 and TIMP-2.
While our data support our conclusion that the
inhibitory eﬀe c to fe a c hc o m p o u n di sm e d i a t e db yi t se ﬀects
on IAP cleavage, we can not rule out the possibility that
the compounds also have additional inhibitory eﬀects on
the IGF-I signaling pathways that are not mediated through
acceleration of IAP cleavage. IAP is a binding site for the
matricellular protein Thrombospondin-1 (TS-1) [33]. We
have shown previously that there is a signiﬁcant increase in
TS-1 deposition in the matrix surrounding SMC cultured
in high glucose compared with that of normal glucose and
that TS-1 is a potent stimulator of IGF-I signaling [26, 33].
One alternative mechanism distinct from the regulation of
IAPcleavagebyMMP-2isthepossibilitythatthecompounds
regulate TS-1 association with IAP and thereby regulating its
susceptibility to cleavage.
The results of these studies indicate that in vivo studies
are now warranted to determine the eﬃcacy of the positive
hit compounds at inhibiting IGF-I-stimulated REC and/or
SMC proliferation in vivo. We have shown that inhibition
of IAP association with SHPS-1 in diabetic mice results in
attenuation of SMC proliferation [32]. Since acceleration of
IAP cleavage led to a similar change in IGF-I activity in vitro
our ﬁndings support the conclusion that these compounds
will be eﬀective in vivo in inhibiting SMC responses to IGF-
I. A therapy that accelerates IAP cleavage would be designed
to reverse a qualitatively distinct pathophysiologic eﬀect of
hyperglycemia and thus should allow normal maintenance
of IGF-I signaling in vascular cells.
In conclusion, in this study we developed a cell-based
ELISA to allow the high-throughput screening of small
molecules to identify those that accelerated IAP cleavage.
This assay is now available for the screening of second
generation compounds derived from the most promising
lead compounds. Given the in vitro data obtained with
the active compounds it seems highly probable that with
further development and testing we could conclude a novel
compound could be identiﬁed when used either alone that
or in combination with other therapies to prevent or treat
vascular complications associated with diabetes.
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